Epitan resumes sustained release trial

By Renate Krelle
Tuesday, 06 July, 2004

Melbourne-based EpiTan (ASX:EPT) has resumed its trial of the sustained release implant for tanning drug Melanotan.

The trial is being conducted at Queensland's Clive Berghofer Cancer Research Centre with a new significantly smaller solid injectable. It will be used to determine the optimal dose for the final commercial formulation of Melanotan.

Epitan executive chairman Dr Wayne Millen said the new implant was able to be injected with a 16 gauge needle.

Lipid science receives new Australia-led online hub

The Lipid Network launched this month to build links between researchers, clinicians and industry...

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

Content from other channels on our network

Community food network closes its soft plastics recycling loop

Real-time monitoring reduces risk at pumping station

Victorian oil refinery fire may impact fuel supply

Leafy greens identified as potential metal mining tools

Smart monitoring helps tram network cut water use by 70%

Six on the shelf: on-the-go protein, ready-to-cook veggies and more

What can food manufacturers learn from viral food trends?

Lion 'flicks the switch' to electric at Speight's Brewery

NZ Winegrowers calls for a White Wine Emoji

Nutrition claims compliance, fresh produce guide updated

AI won’t restart your plant: Why practical skills matter more than ever

POSCO Holdings steps up HILT CRC partnership

Melbourne company gets funding for new battery manufacturing model

Hazer and KBR complete commercial-scale hydrogen plant design

Calibration explained: principles, processes and modern reporting